The possible role of insulin-like growth factor-1 in osteosarcoma.
Osteosarcoma (OS) is a common malignant tumor of bone, of which clear understanding of molecular pathologic process is not yet possible. Insulin-like growth factor-1 (IGF-1) is a hormone that plays vital role in development and function of many tissues. Unfortunately, IGF-1 and its receptor (IGF-1R)'s over-expression have been implicated in carcinogenesis, and indicated to constitute a risk factor for the development of multiple human cancers, including OS. Increased levels of IGF-1 and IGF-1R have been reported in OS, leading to cancer progression through transformation, proliferation, pro-metastasis, and decreased susceptibility to apoptosis. Over-expression of IGF-1/IGF-1R signaling also contributes to tumor cell survival, metastasis, and resistance to chemotherapeutic drugs. IGF-1 has been included as an OS marker recently, and targeting IGF-1 is an interesting and promising approach in OS therapeutics. However more investigations with clinical trials are necessary to validate the use of drugs against IGF-1 that may provide a basis for new therapeutic approaches to treat this devastating disease. This review article focused on the role of IGF-1/IGF-1R in OS progression and therapeutic aspects of OS targeting IGF-1.